Syntheses, biological evaluation, and molecular modeling of 18F-labeled 4-anilidopiperidines as μ-opioid receptor imaging agents

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7720-7732

  Henriksen, Gjermund ^a   Platzer, Stefan ^a   Marton, János ^b   Hauser, Andrea ^a   Berthele, Achim ^a   Schwaiger, Markus ^a   Marinelli, Luciana ^c   Lavecchia, Antonio ^c   Novellino, Ettore ^c   Wester, Hans Jürgen ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ABX Advanced Biochemical Compounds GmbH   (Germany)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 ANILIDOPIPERIDINE DERIVATIVE; FLUORINE 18; METHYL 4 [N (1 OXOPROPYL) N PHENYLAMINO] 1 (5 FLUOROPENTYL) 4 PIPERIDINECARBOXYLATE F 18; MU OPIATE RECEPTOR; N PHENYL N [4 (METHOXYMETHYL) 1 (2 THIENYLETHYL) 4 PIPERIDINYL] 2 FLUOROPROPANAMIDE F 18; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN REGION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FLUORINATION; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; ISOTOPE LABELING; MALE; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 28144452230     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0507274     Document Type: Article

References (69)

1. Matthes, H. W.; Maldonado, R.; Simonin, F.; Valverde, O.; Slowe, S.; Kitchen, I.; Befort, K.; Dierich, A.; Le Meur, M.; Dolle, P.; Tzavara, E.; Hanoune, J.; Roques, B. P.; Kieffer, B. L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383, 819-823.
2. Rubinstein, M.; Mogil, J. S.; Japon, M.; Chan, E. C.; Allen, R. G.; Low, M. J. Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 3995-4000.
3. Zubieta, J. K.; Smith, Y. R.; Bueller, J. A.; Xu, Y.; Kilbourn, M. R.; Jewett, D. M.; Meyer, C. R.; Koeppe, R. A.; Stohler, C. S. Regional mu-opioid receptor regulation of sensory and affective dimensions of pain. Science 2001, 293, 311-315.
4. 11C]carfentanil and positron emission tomographpy (PET). Pain 2002, 99, 589-598.
5. Zubieta, J. K.; Gorelick, D. A.; Stauffer, R.; Ravert, H. T.; Dannals, R. F.; Frost, J. J. Increased mu opioid receptor binding detected by PET in cocaine dependent men is associated with cocaine craving. Nature Med. 1996, 2, 1225-1229.
6. 11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol. Psych. 2004, 55, 255-262.
7. Liberzon, I.; Zubieta, J. K.; Fig, L. M.; Phan, K. L.; Koeppe, R. A.; Taylor S. F. μ-Opioid receptors and limbic responses to aversive emotional stimuli. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 7084-7089.
8. Halldin, C.; Gulyás, B.; Langer, O.; Farde, L. Brain radioligands-State of the art and new trends. Q. J. Nucl. Med. 2001, 45, 139-152.
9. Hartvig, P.; Bergström, M.; Längstem, B. Use of positron emission tomography in analyzing receptor function in vivo. Toxicol. Lett. 2001, 120, 243-251.
10. Laruelle, M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000, 20, 423-451.
11. Laruelle, M.; Huang, Y. Vulnerability of Positron Emission Tomography radiotracers to endogenous competition. Q. J. Nucl. Med. 2001, 45, 124-138.
12. (a) Helsley, G. C.; Lunsford, C. D.; Welstead, W. J., Jr.; Boswell, R. F.; Funderburk, W. H.; Johnson, D. N. Synthesis and analgesic activity of aome 1-substituted 3-pyrroldinylanilides and dihydrobenzoxazinones. J. Med. Chem. 1969, 12, 583-586.
13. (b) Finney, Z. G.; Riley, T. N. 4-anilidopiperidine analgesics. 3. 1-substituted 4-(propananilido) perhydroazepines as ring- expanded analogues. J. Med. Chem. 1980, 23, 895-899.
14. (c) Borne, R. F.; Law, S.-Y.; Kapeghian, J. C.; Masten, L. W. Evaluation of 2-azabicyclo[2.2.2] octane analogues of 4-anilidopiperidine analgesics. J. Pharm. Sci. 1980, 69, 1104-1106.
15. (d) Fernandez, M. J.; Huertas, R. M.; Galvez, E.; Orjales, A.; Berisa, A.; Labeaga, L.; Gago, F.; Fonseca, I.; Sanz-Aparicio, J.; Cano, F. H.; Albert, A.; Fayor, J. Synthesis, and structural, conformational and pharmacolgical studies of new fentanyl derivatives of the norgranatane System. J. Chem. Soc., Perkin Trans. 2 1992, 687-695.
16. (e) Van Daele, P. G.; De Bruyn, M. F.; Boey, J. M.; Sanczuk, S.; Agten, J. T.; Janssen, P. A. Synthetic analgesics: N-(1-[2-arylethyl]-4-substituted 4-piperidinyl N-arylalkanamides. Arzneim.-Forsch. Drug Res. 1976, 26, 1521-1531.
17. (a) Colapet, J. A.; Diamantidis, G.; Spencer, H. K.; Spaulding, T. C.; Rudo, F. G. Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines. J. Med. Chem. 1989, 32, 968-974.
18. (b) France, C. P.; Winger, G.; Madzihradsky, F.; Seggel, M. G.; Rice, K. C.; Woods, J. H. Mirfentanil: Pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J. Pharmacol. Exp. Ther. 1991, 258, 502-510.
19. (c) France, C. P.; Gerak, L. R.; Flynn, D.; Winger, G. D.; Medzihradsky, F.; Bagley, J. R.; Brockunier, L. L.; Woods, J. H. Behavioral effects and receptor binding affinities of fentanyl derivatives in rhesus monkeys. J. Pharmacol. Exp. Ther. 1995, 274, 17-28.
20. (d) Cometta-Morini, C.; Maguire, P. A.; Loew, G. H. Molecular determinants of μ-receptor recognition for the fentanyl class of compounds. Mol. Pharmacol. 1992, 41, 185-196.
21. (a) Janssen, P. A. J.; Van Daele, G. H. P. N-(4-piperidinyl)-N- phenylamides and -carbamates. US patent 3,998,834, 1976.
22. (b) Janssen, P. A. J.; Van Daele, G. H. P. N-(4-piperidinyl)-N- phenylamides. US patent 4,179,569, 1979.
23. Fowler, C. B.; Pogozheva, I. D.; Lomize, A. L.; LeVine, H. 3rd; Mosberg, H. I. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints. Biochemistry. 2004, 43, 15796-15810. The model of the μ-receptor is available from the following web site: http://mosberglab-.phar.umich.edu/resources/index.php.
24. Jewett, D. M.; Kilbourn, M. R. In vivo evaluation of new carfentanil-based radioligands for the mu opiate receptor. Nucl. Med. Biol. 2004, 31, 321-325.
25. 11C]carfentanil: a radiopharmaceutical for studying brain μ-opioid receptors by positron emission tomography. Ann. Nucl. Med. 1992, 6, 63-67.
26. 11C]DPN in humans. J. Nucl. Med. 2000, 41, 1279-1286.
27. 11C]carfentanil: reference-tissue methods. Nucl. Med. Biol. 2003, 30, 177-186.
28. Halldin, C.; Swahn, C. G.; Farde, L.; Sedvall, G. Radioligand disposition and metabolism-Key information in drug development. In PET for Drug Development and Evaluation; Comar, D., Ed.; Kluwer Academic Publishers: Boston, 1995; pp 55-61.
29. 18F]FCWAY, an analog of the 5-HT1A receptor antagonist, WAY-100635. Nucl. Med. Biol. 2000, 27, 493-497.
30. 18F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid-phase extractions. Nucl. Med. Biol. 2003, 30, 233-240.
31. Ravert, H. T.; Bencherif, B.; Madar, I.; Frost J. J. PET imaging of opioid receptors in pain: progress and new directions. Curr. Pharm. Des. 2004, 10, 759-768.
32. Brodsky, M.; Elliott, K.; Hynansky, A.; Jenab, S.; Inturrisi, C. E. Quantitation of mu-opioid receptor (MOR-1) mRNA in selected regions of the rat CNS. Neuroreport 1995, 6, 725-729.
33. Raynor, K.; Kong, H.; Chen, Y.; Yasuda, K.; Yu, L.; Bell, G. I.; Reisine, T. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol. Pharm. 1994, 45, 330-334.
34. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of Rhodopsin: a G protein-coupled receptor. Science 2000, 289, 739-745.
35. (a) Strahs, D.; Weinstein, H. Comparative modeling and molecular dynamics studies of the δ, κ, and μ-opioid receptors. Protein Eng. 1997, 10, 1019-1038.
36. (b) Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys. J. 1998, 75, 612-634.
37. (c) Filizola, M.; Laakkonen, L.; Loew, G. H. 3D modeling, ligand binding, and activation studies of the cloned mouse δ, μ, and κ-opioid receptors. Protein Eng. 1999, 12, 927-942.
38. (d) Zhang, Y.; Sham, Y. Y.; Rajamani, R.; Gao, J.; Portoghese, P. S. Homology modeling and molecular dynamics simulation of the mu opioid receptor in a membrane-aqueous system. Chem. Bio Chem. 2005, 6, 853-859.
39. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins Struct. Funct. Genet. 2003, 50, 5-25.
40. (a) Okada, T.; Ernst, O. P.; Palczewski, K.; Hofmann, K. P. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem. Sci. 2001, 26, 318-324.
41. (b) Hubbell, W. L.; Altenbach, C.; Hubbell, C. M.; Khorana, H. G. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 2003, 63, 243-290.
42. (a) Peeters, O. M.; Blaton, N. M.; De Ranter, C. J.; van Herk, A. M.; Goubitz, K.; Crystal and Molecular Structure of N-[1-(2-phenylethyl)-4- piperidinylium]-N-phenylpropanamide (fentanyl) citrate-toluene Solvate. J. Cryst. Mol. Struct. 1979, 9, 153-161.
43. (b) Flippen-Anderson, J. L.; George, C.; Bertha, C. M.; Rice, K. C. X-ray crystal structures of potent opioid receptor ligands: Etonitazene, cis-(+)-3-Methylfentanyl, Etorphine, Diprenorphine, and Buprenorphine. Heterocycles 1994, 39, 751-766.
44. Brine, G. A.; Stark, P. A.; Liu, Y.; Carroll, F. I.; Singh, P.; Xu, H.; Rothman, R. B. Enantiomers of diastereomeric cis-N-[1-(2-hydroxy-2-phenylethyl)- 3-methyl-4-piperidyl]-N-phenylpropanamides: Synthesis, X-ray analysis, and biological activities. J. Med. Chem. 1995, 38, 1547-1557.
45. Brine, G. A.; Boldt, K. G.; Huang, P.-T.; Sawyer, D. K.; Carroll, F. I. Carbon-13 nuclear magnetic resonance spectra of fentanyl analogues. J. Heterocycl. Chem. 1989, 26, 677-686.
46. (a) Martins, J.; Andrews, P. Conformation-activity relationships of opiate analgesics. J. Comput.-Aided Mol. Des. 1987, 1, 53-72.
47. (b) Subramanian, G.; Ferguson, D. M. Conformational landscape of selective mu-opioid agonists in gas phase and in aqueous solution: the fentanyl series. Drug Des. Discovery 2000, 17, 55-67.
48. 27
49. (a) Surratt, C. K.; Johnson, P. S.; Moriwaki, A.; Seidleck, B. K.; Blaschak, C. J.; Wang, J. B.; Uhl, G. R.m-Opiate receptor: Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. Biol. Chem. 1994, 269, 20548-20553.
50. (b) Mansour A.; Taylor L. P.; Fine J. L.; Thompson R. C.; Hoversten M. T.; Mosberg H. I.; Watson S. J.; Akil H. Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J. Neurochem. 1997, 68, 344-353.
51. (c) Li, J. G.; Chen, C.; Yin J.; Rice, K.; Zhang, Y.; Matecka, D.; de Riel, J. K.; DesJarlais, R. L.; Liu-Chen, L. Y. ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone. Life Sci. 1999, 65, 175-85.
52. 3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor. J Biol. Chem. 1996, 271, 21422-21429.
53. Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Opioid Receptor Three-dimensional Structures from Distance Geometry Calculations with Hydrogen Bonding Constraints. Biophys. J. 1998, 75, 612-634.
54. Tang, Y.; Chen, K. X.; Jiang, H. L.; Wang, Z. X.; Ji, R. Y.; Chi, Z. Q. Molecular Modeling of the μ-Opioid Receptor and its Interaction with OHMefentanyl. Acta Pharmacol. Sin. 1996,17, 156-160.
55. Xu, H.; Lu, Y.-F.; Partilla, J. S.; Zheng, Q.-X.; Wang, J.-B.; Brine, G. A.; Carroll, I.; Rice, K. C.; Chen, K.-X.; Chi, Z.-Q.; Rothman, R. B. Opioid Peptide Receptor Studies, 11: Involvement of Tyr148, Trp318, and His319 of the Rat μ-Opioid Receptor in Binding of μ-Selective Ligands. Synapse 1999, 32, 23-28.
56. Ulens, C.; Van Boven, M.; Daenens, P.; Tytgat, J.; Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity. J. Pharmacol. Exp. Ther. 2000, 294, 1024-1033.
57. Shi, L.; Liapakis, G.; Xu, R.; Guarnieri, F.; Ballesteros, J. A.; Javitch, J. A. α-2-adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 2002, 277, 40989-40996.
58. Mouledous, L.; Topham, C. M.; Moisand, C.; Mollereau, C.; Meunier, J. C. Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain. Mol. Pharmacol. 2000, 57, 495-502.
59. Subramanian, G.; Paterlini, M. G.; Portoghese, P. S.; Ferguson, D. M. Molecular Docking Reveals a Novel Binding Site Model for Fentanyl at the μ-Opioid Receptor. J. Med. Chem. 2000, 43, 381-391.
60. 18F- cyprodime. J. Labeld. Compds. Radiopharm. 2003, 46, S175.
61. 18F-fluoroalkyl esters of Carfentanil. J. Labelled Compds. Radiopharm. 2005, 48, 1-9.
62. Dolbier, W. R.; Lee, S. K.; Phanstiel, O. The in situ generation and trapping of some fluorine substituted ketenes. Tetrahedron 1991, 47, 2065-2072.
63. 18F]fluorocarboxylic acids. Appl Radiat. Isot. 1994, 6, 715-727.
64. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
65. SYBYL Molecular Modeling System (version 6.8), TRIPOS Assoc., St. Louis, MO.
66. Head, J.; Zerner, M. C. A Broyden-Fletcher-Goldfarb-Shannon optimization procedure for molecular geometries. Chem. Phys. Lett. 1985, 122, 264-274.
67. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.
68. Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imag. Biol. 2003, 5, 376-389.
69. 18F-labeled sufentanil for PET-imaging of mu-opioid receptors. Bioorg. Med. Chem. Lett. 2005, 15, 1773-1777.